Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-06-22
2002-03-26
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S449000
Reexamination Certificate
active
06362214
ABSTRACT:
The invention relates to a new form of ramatroban which is thermodynamically stable at room temperature, a process for its preparation, pharmaceuticals comprising this form, and their use in the control of diseases.
The preparation and use of ramatroban as a thromboxane A2 antagonist has already been disclosed in EP 242 518. U.S. Pat. No. 4,827,032, which is hereby incorporated by reference herein.
In the manner described there, ramatroban is obtained in the form of a crystal modification which is designated in the following text as modification II. Mod. II has a melting point of 137° C. and a malt enthalpy of 80 J/g (DSC, heating rate 2 K min
−1
) and a characteristic X-ray diffractogram, IR spectrum,
13
C-solid state NMR spectrum, FIR spectrum, Raman spectrum (FIGS.
1
-
6
). It has now been found that Mod. II is metastable and therefore is not suitable for use in pharmaceutical formulations, such as, for example, solid and semi-solid preparations.
Surprisingly, a second modification of ramatroban has now been found which is thermodynamically stable and is also stable on storage after processing by means of suspensions and is therefore particularly suitable for use in pharmaceutical formulations, such as, for example, suspensions or creams, but also in other preparations which are prepared by means of suspended active compound, such as, for example, in aqueous granulation or wet-grinding. This new modification is designated in the following text as modification I. The present invention also relates to pharmaceutical formulations which contain ramatroban in the modification I as active substance. The formulation can contain one or more pharmaceutically acceptable auxiliaries, such as, for example, binders, solvents, fillers, etc.
J. Halbelian, W. McCrowne, J. Pharm. Sci. 58 (1969) 911, and J.-0. Henck et al., Pharm. Ind. 59 (1997) 165-169 disclose that when using a thermodynamically metastable polymorphic form in solid and semi-solid formulations, such as, for example, tablets, suspensions and ointments, the stable form can result. As an attendant phenomenon here, undesired crystal growth, changes in the bioavailability, caking, etc. are observed. The two crystal modifications of ramatroban differ in their solubility at-room temperature by 60%. By means of the use according to the invention of the stable modification I, it is ensured that no change in solubility can occur as a result of conversion. This increases the safety of preparations of ramatroban and the risk for the patients is thus reduced.
In comparison with Mod. II, Mod. I has a clearly distinguishable DSC thermogram, X-ray diffractogram,
13
C-solid state NMR spectrum, FIR spectrum and Raman spectrum (FIGS.
1
-
6
). The melting point of Mod. I is 151° C. and the melt enthalpy is 87 J/g.
The DSC and TGA thermograms were obtained using a DSC 7 and TGA 7 from Perkin-Elmer. The X-ray diffractograms were recorded in a Stoe transmission diffractometer. The IR, FIR and Raman spectra were recorded using Fourier IR spectrometers IFS 66 (IR), IFS 66v (FIR) and IFS 88 (Raman) from Bruker. The
13
C-solid state NMR spectra were recorded using a Bruker MSL 300.
The crystal modification of ramatroban is employed in high purity in pharmaceutical formulations. For reasons of stability, Mod. I should not contain relatively large proportions of Mod. II. A grade of active compound with less than 10% of Mod. II, very particularly preferably with less than 5%, is preferred.
Mod. I is prepared by suspending ramatroban of modification II in water or inert substances, e.g. in lower alcohols, ketones or alkanes, seeding with crystals of Modification I and stirring until the desired degree of conversion is achieved, particularly preferably until quantitative conversion to Mod. I. As a rule, this conversion takes place at 20-50° C., preferably at 40° C. The crystals of Mod. I obtained are separated off and, to remove solvent present, dried to constant weight at room temperature in vacuo or at elevated temperature.
To prepare the seed crystals needed, the active compound is thoroughly melted and then rapidly cooled to room temperature. The amorphous form of the active compound thus obtained is suspended in an inert solvent at room temperature and stirred until it is completely converted into the thermodynamically stable crystal modification. The residue is filtered and dried to constant mass in vacuo.
REFERENCES:
patent: 4827032 (1989-05-01), Böshagen et al.
patent: 5684158 (1997-11-01), Samaan et al.
patent: 87100773 (1987-02-01), None
patent: 0242518 (1987-10-01), None
patent: 0728743 (1996-08-01), None
L. Kofler, A. Kofler, M. Brandstätter, Thermo-Mikromethoden zur Kennzeichnung organischer Stoffe und Stoffgemische, Verlag Chemie GmbH, 1954, Weinheim/Bergstrasse, pp. 111-201.
A. Grunenberg, Polymorphie und Thermische Analyse, Pharmazie in unserer Zeit 26 (1997) 224-231.
U. Rosentreter, H. Böshagen, F. Seuter, E. Perzborn, V. B. Fiedler, “Sysnthesis and Absolute Configuration of the New Thromboxane Antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropanoic Acid and Comparison with its Enantiomer”, Arznei.-Forsch./Drug Res., 39(II): 1519-1521 (1989).
OECD-Guidelines for Testing Chemicals, Section 1, Physical-chemical Properties. Water solubility, Method No. 105, Paris 1981.
A. Burger, R. Ramberger, “On the Polymorphism of Pharmaceuticals and Other Molecular Crystals”, Mikrochim. Acta 1979 II, 259-271, 273-316.
A. Grunenberg, J.-O. Henck, H. W. Siesler, “Theoretical Derivation and Practical Application of Energy/temperature diagrams as an Instrument in Preformulation Studies of Polymorphic Drug Substances”, Int. J. Pharm., 128: 147-158 (1996).
Grunenberg Alfons
Voges Klaus-Peter
Wahl Karl-Heinz
Bayer Yakuhin, Ltd.
Chiu Jerrie L.
Powers Fiona T.
LandOfFree
Thermodynamically stable form of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thermodynamically stable form of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thermodynamically stable form of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2850630